Quarterly ResultMay 4, 2026, 04:14 PM
Biohaven Q1 Net Loss $(130.5M); R&D Down 44.7%; Equity Up to $129.5M
AI Summary
Biohaven Ltd. reported a reduced net loss for Q1 2026, decreasing to $(130.5) million from $(221.7) million in Q1 2025, driven by a significant reduction in operating expenses, particularly R&D. The company's cash and cash equivalents increased to $273.1 million, and total shareholders' equity rose to $129.5 million, largely due to $178.9 million in proceeds from common share issuance. Biohaven continues to fund operations through equity and debt, including senior secured notes, and expects current liquidity to last at least one year.
Key Highlights
- Net loss decreased to $(130.5) million in Q1 2026 from $(221.7) million in Q1 2025.
- Net loss per share improved to $(0.88) from $(2.17) year-over-year.
- Research and development expenses fell 44.7% to $103.8 million.
- Total operating expenses decreased 41.1% to $130.4 million.
- Cash and cash equivalents increased to $273.1 million as of March 31, 2026.
- Total shareholders' equity rose to $129.5 million from $52.1 million.
- Proceeds from common share issuance totaled $178.9 million in Q1 2026.
- Net cash used in operating activities reduced to $(149.9) million.
Price Impact
More from BHVN